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 INTRODUCTION: From 2008 – 2012, approximately 12% of colorectal cancers (CRC) were diagnosed in patients 85 years of age or older.  This age group currently represents 2% of the U.S. 
population and it is estimated that by 2040, this cohort will more 
than double in size, to 14.7 million people. Consequently, the number 
of CRC diagnosed in this age group will rise steadily.
OBJECTIVE: To examine outcomes of nonagenarians diagnosed with 
CRC, as well as to determine some of the factors involved in the 
decision-making process regarding choice of treatment.
DESIGN: Retrospective review of nonagenarians patients diagnosed 
with CRC between 2005 and 2014 from the LVHN Tumor Registry. 
We identified patients undergoing any surgical intervention and 
those who declined any treatment, and compared the 1-year survival 
between the 2 groups. We also examined the factors involved in 
treatment decision, including:
 •  Modified Frailty Score (MFS)
 •  Presence of surrogate decision-maker
 •  Presence of metastatic disease
 •  Pre-hospital residence
For patients who underwent surgery, we examined their outcomes, 
including postoperative morbidity, 30-day mortality and long-term 
survival.  Statistical analysis was performed using Chi-square 
analysis and logistic regression.
SETTINGS: This study was conducted at a single tertiary center
PATIENTS: A total of 100 patients were included, with a median 
follow-up of 12 months. 65 patients underwent surgical intervention, 
while 35 patients declined any treatment.
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CONCLUSIONS
Nonagenarian patients diagnosed with CRC have a significantly higher 1-year survival with surgical intervention compared to those who decline 
treatment.  Surgery can be performed in these patients with acceptable postoperative mortality and 1-yr survival. MFS was not useful as a predictor in 
neither treatment decision-making nor surgical outcomes for these patients.
RESULTS
Patients in the treatment group had a higher 1-year survival compared to those who chose no 
treatment (53.8% vs 17.1%, p<0.0005) and a Mean survival of 23 months vs 5.4 months.  
Within the surgical treatment group:
•  Postoperative mortality (13.8%) 
•  Procedure with curative intent (80.3%).  
 −  Mortality within this subgroup (8.8%).
•  Postoperative morbidity (35.4%).
Univariate analysis:
•  Presence of surrogate decision-maker (p=0.008) and metastatic 
    disease (p<0.0001) were predictive of declining treatment. 
Multivariate analysis:
•  Presence of metastatic disease associated with declining treatment (p<0.0001). 
Increased frailty (MFS 3+) was not found in patients declining treatment or in patients with 
poor surgical outcomes.  In the treatment group, increased MFS was associated longer length 
of stay (12.1 vs 8.2 days, p=0.028), but not associated with delayed return of bowel function, 
increased surgical site infection or 30-day readmission rate.
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Table 1. Patient Characteristics and Results
 Surgery No Surgery p-value
n 65 35 
Age (mean) 92 93
Gender
Men, n (%) 16 (24.6) 14 (40) 0.117
Women, n (%) 49 (75.4) 21 (60)
Surrogate, n (%) 5 (7.7) 10 (28.6) 0.008
Assisted living, n (%) 15 (21.1) 11 (31.4) 0.474
Metastatic disease, n (%) 6 (9.2) 14 (40) <0.001
Modified Frailty Score
Low (0-2), n (%) 27 (41.5) 18 (51.4) 0.402
High (3+), n (%) 38 (58.5) 17 (48.6)
1-year survival, n (%) 35 (53.8) 6 (17.1) 0.0005
5-year survival, n (%) 7 (9.9) 0 (0) NA
Table 2. Surgery Subgroup Comparison
Overall MFS Low MFS High p-value
n 65 27 38
Length of stay, days 10.5 8.2 12 0.034
Return of bowel function, days 4.49 4.63 4.39 0.667
SSI, n (%) 10 (15) 3 (11) 7 (18) 0.503
Anastomotic leak, n 1 1 0 NA
30-day Readmission, n (%) 12 (18.5) 4 (14.8) 8 (21) 0.747
Postop Mortality, n (%) 9 (13.8) 3 (11) 6 (15.8) 0.724
Postop complications, n (%) 23 (35.4) 11 (37) 12 (31.6) 0.6045
